Biodexa Pharmaceuticals (BDRX) Current Deferred Revenue (2013 - 2025)
Biodexa Pharmaceuticals' (BDRX) quarterly Current Deferred Revenue came in at $748883.6 in Q4 2025, up 8.45% year-over-year from $690524.0 in Q4 2024, and up 7.54% quarter-over-quarter from $696371.8 in Q2 2025.
Powered by 
Analysis
Biodexa Pharmaceuticals (BDRX) Current Deferred Revenue (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $748883.6 for Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 8.45% year-over-year to $748883.6; the TTM figure through Dec 2025 stood at $748883.6 (up 8.45% YoY), while the FY2025 annual figure was $742321.3, up 7.94% from the prior year.
- Current Deferred Revenue came in at $748883.6 for Q4 2025 at Biodexa Pharmaceuticals, up from $696371.8 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $748883.6 in Q4 2025 to a low of $579359.3 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Biodexa Pharmaceuticals | 53.69 Mn | 42.34 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 748,883.57 |
| Jun 30, 2025 | 696,371.85 |
| Dec 31, 2024 | 690,523.99 |
| Jun 30, 2024 | 579,359.32 |
| Dec 31, 2015 | 2.09 Mn |
| Dec 31, 2014 | 248,751.29 |
| Dec 31, 2013 | 238,003.77 |